Encouraging five year clinical data for novel next generation Immuno-Oncology therapy In lung cancer presented at ESMO 2017 Congress

Oct 12, 2017

Copenhagen, Denmark – October 12, 2017: IO Biotech, a private company developing novel immuno-oncology therapies targeting immune checkpoint inhibitory targets to treat cancer, today announced encouraging five year clinical data for novel next generation Immuno-Oncology therapy in lung cancer presented at ESMO 2017 Congress

Other news

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial